ISSN: 1759-720X

Journal Home

Journal Guideline

Therapeutic Advances in Musculoskeletal Disease Q1 Unclaimed

SAGE Publications Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Therapeutic Advances in Musculoskeletal Disease is a journal indexed in SJR in Orthopedics and Sports Medicine with an H index of 48. It has a price of 4375 €. It has an SJR impact factor of 1,061 and it has a best quartile of Q1. It has an SJR impact factor of 1,061.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Orthopedics and Sports Medicine (Q1) Rheumatology (Q2)

Price

4375 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Therapeutic Advances in Musculoskeletal Disease

1,061

SJR Impact factor

48

H Index

47

Total Docs (Last Year)

298

Total Docs (3 years)

2941

Total Refs

1099

Total Cites (3 years)

293

Citable Docs (3 years)

3.49

Cites/Doc (2 years)

62.57

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

British Journal of Sports Medicine Q1
Sports Medicine Q1
Journal of Cachexia, Sarcopenia and Muscle Q1
Journal of Sport and Health Science Q1
American Journal of Sports Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting

The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis

Management of antiphospholipid syndrome

Fibrin glue for olecranon bursitis: a case report

Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions

Bisphosphonate drug holiday: who, when and how long

Biologicals and bone loss

Efficacy and safety of febuxostat in patients with hyperuricemia and gout

Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

Biologic agents in rheumatoid arthritis: temporal trend of incremental benefits

Making the next steps in psoriatic arthritis management: current status and future directions

Management and evaluation of extra-articular manifestations in spondyloarthritis

SHOW MORE ARTICLES

Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis

Editorial

Hyperbaric Oxygen Effects on Sports Injuries

Malignancy Risk in Vasculitis

Important issues at heart: cardiovascular risk management in rheumatoid arthritis

Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence

Managing hip and knee osteoarthritis with exercise: what is the best prescription?

Evidence-based management of Raynaud's phenomenon

Analytical considerations for the biochemical assessment of vitamin D status

Physical Functioning Measures and Risk of Falling in Older People Living in Residential Aged Care Facilities

Management of primary Sjogren's syndrome: recent developments and new classification criteria

Using hand bone mass measurements to assess progression of rheumatoid arthritis